Nuvalent, Inc. (NUVL) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Cambridge, MA, United States. The current CEO is James R. Porter.
NUVL has IPO date of 2021-07-29, 162 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $7.69B.
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. The company's lead programs include NVL-520, a brain-penetrant ROS1-selective inhibitor currently in Phase I development designed to overcome drug resistance mutations, and NVL-655, a brain-penetrant ALK-selective inhibitor in Phase I/II clinical trials addressing treatment resistance and brain metastases. Founded in 2017 and headquartered in Cambridge, Massachusetts, Nuvalent is advancing precision oncology solutions for patients with ROS1 and ALK-driven cancers.
